Patent law tilts sharply toward holders; challengers face new barriers.

What it does

The PREVAIL Act amends U.S. patent law to make it harder for competitors to challenge patents through administrative proceedings (inter partes review and post-grant review). It restricts who can file these challenges, limits repetitive filings, requires higher evidentiary standards for challengers, and prevents patent owners from being sued in court or before the International Trade Commission on the same validity grounds once an administrative challenge is filed. It also stops the USPTO from diverting patent fees to other government programs and creates a dedicated patent fee fund.

Why we flagged it

The bill's core mechanism restricts administrative patent challenges (inter partes and post-grant review) through higher barriers, repetition limits, and estoppel rules, while simultaneously protecting USPTO fee autonomy from congressional diversion. The restrictions favor patent holders; the fee autonomy is structural reform.

What the text implies

• The 'single forum' provision (Section 4 & 5) bars petitioners from raising validity challenges in federal court or before the ITC if an administrative review is instituted, effectively forcing all challenges into a single, patent-holder-friendly venue and preventing parallel litigation strategies.
• The 'real party in interest' expansion (Sections 4 & 5) treats any entity making a financial contribution to a challenge as a party, potentially capturing nonprofits, universities, and public-interest organizations that fund patent challenges, subjecting them to estoppel and joinder rules.
• The 'exceptional circumstances' standard for rejecting repetitive petitions is undefined and grants the USPTO Director broad discretion to reject challenges without clear criteria, creating unpredictability for challengers.
• The presumption of validity and clear-and-convincing-evidence burden (Sections 4 & 5) make it substantially harder for challengers to invalidate patents, shifting the evidentiary balance away from the historical 'preponderance' standard and favoring patent holders.
• The fee autonomy provisions (Section 7) insulate the USPTO from congressional oversight of patent fee use, potentially allowing fee increases without legislative check and reducing transparency in how patent revenues are deployed.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill strengthens patent protections, which may encourage innovation and investment in new inventions—a public benefit. However, it simultaneously restricts ordinary citizens' and small competitors' ability to challenge potentially invalid patents through affordable administrative proceedings, shifting power toward large patent holders and making it costlier for the public to challenge questionable patents in court or before regulators.

Who stands to gain

• patent holders and patent-intensive companies
• large technology and pharmaceutical firms with substantial patent portfolios
• patent licensing entities and patent assertion entities (PAEs)
• the USPTO (through fee autonomy and increased fee collection authority)

Named in the bill

USPTO (U.S. Patent and Trademark Office), Patent Trial and Appeal Board (PTAB), Director of the USPTO, Federal courts (Section 1338 jurisdiction), International Trade Commission (ITC), Small Business Administration, Institutions of higher education, Nonprofit organizations (501(c)(3))

Where it stands

2 cosponsors: 2 Democrats.

• May 1, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 1, 2025 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

32 lobbying clients named this bill on 42 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $38,778,909 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

Nathaniel Moran, the sponsor, reported $856,691 in PAC receipts in the 2026 cycle. $11,000 of that came from 2 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Amazon.com Services LLC — $4,360,000 on 1 filing
• Apple Inc — $2,740,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.